First Molecular Typing of Cryptococcemia-Causing Cryptococcus in Central-West Brazil

Mycopathologia

Volumn 176, Issue 3-4, 2013, Pages 267-272

  de Sousa Tsujisaki, Rosianne Assis ^a   Paniago, Anamaria Mello Miranda ^a   da Costa Lima Júnior, Manoel Sebastião ^b   de Souza Olartechea de Alencar, Débora ^a   Spositto, Fernanda Luíza Espinosa ^a   de Oliveira Nunes, Maína ^c   Trilles, Luciana ^d   Chang, Marilene Rodrigues ^a  

^a FEDERAL UNIVERSITY OF MATO GROSSO DO SUL   (Brazil)

^b Federal Institute of Mato Grosso Do sul   (Brazil)

^c Brazilian Hospital Services Company EBSERH   (Brazil)

^d Funda??o Oswaldo Cruz   (Brazil)

Author keywords

Cryptococcemia; Cryptococcus gattii; Cryptococcus neoformans; HIV negative; Molecular typing

Indexed keywords

CRYPTOCOCCUS GATTII; CRYPTOCOCCUS SP.; FILOBASIDIELLA NEOFORMANS; FUNGI;

ANTIFUNGAL AGENT; FUNGAL PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAZIL; CHILD; CLASSIFICATION; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; FEMALE; FUNGEMIA; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MALE; METHODOLOGY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; BRAZIL; CHILD; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; FEMALE; FUNGAL PROTEINS; FUNGEMIA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; MYCOLOGICAL TYPING TECHNIQUES; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; YOUNG ADULT;

EID: 84884858537     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-013-9676-6     Document Type: Article

References (33)

1. Casadevall A, Perfect JR. Cryptococcus neoformans. Washington, DC: American Society for Microbiology; 1998.
2. Kwon-Chung KJ, Varma A. Do major species concepts support one, two or more species within Cryptococcus neoformans? FEMS Yeast Res. 2006;6(4): 574-87.
3. Meyer W, Castañeda A, Jackson S, Huynh M, Castañeda E, IberoAmerican Cryptococcal Study Group. Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis. 2003;9(2): 189-95.
4. Jean SS, Fang CT, Shau WY, Chen YC, Chang SC, Hsueh PR, et al. Cryptococcaemia: clinical features and prognostic factors. QJM. 2002;95(8): 511-8.
5. Pasqualotto AC, Severo CB, Oliveira FM, Severo LC. Cryptococcemia: an analysis of 28 cases with emphasis on the clinical outcome and its etiologic agent. Rev Iberoam Micol. 2004;21(3): 143-6.
6. Choi HY, Choe JK, Lee YB. Hodgkin's disease complicated by cryptococcemia-one case report. Yonsei Med J. 1970;11(2): 173-81.
7. Fujita Y, Kasahara K, Uno K, Konishi M, Maeda K, Yoshimoto E, et al. Amphotericin B-induced nephrogenic diabetes insipidus in a case of cryptococcemia. Intern Med. 2005;44(5): 458-61.
8. Yehia BR, Eberlein M, Sisson SD, Hager DN. Disseminated cryptococcosis with meningitis, peritonitis, and cryptococcemia in a HIV-negative patient with cirrhosis: a case report. Cases J. 2009; doi: 10. 1186/1757-1626-2-170.
9. Zaharatos GJ, Behr MA, Libman MD. Profound T-lymphocytopenia and cryptococcemia in a human immunodeficiency virus-seronegative patient with disseminated tuberculosis. Clin Infect Dis. 2001;33(11): e125-8.
10. Chong HS, Dagg R, Malik R, Chen S, Carter D. In vitro susceptibility of the yeast pathogen Cryptococcus to fluconazole and other azoles varies with molecular genotype. J Clin Microbiol. 2010; doi: 10. 1128/JCM. 01271-10.
11. Trilles L, Meyer W, Wanke B, Guarro J, Lazéra M. Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex. Med Mycol. 2012; doi: 10. 3109/13693786. 2011. 602126.
12. Kwon-Chung KJ, Polacheck I, Bennett JE. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol. 1982;15(3): 535-7.
13. Trilles L, Lazéra MS, Wanke B, Oliveira RV, Barbosa GG, Nishikawa MM, et al. Regional pattern of the molecular types of Cryptococcus neoformans and Cryptococcus gattii in Brazil. Mem Inst Oswaldo Cruz. 2008;103(5): 455-62.
14. Ferrer C, Colom F, Frasés S, Mulet E, Abad JL, Alió JL. Detection and identification of fungal pathogens by PCR and by ITS2 and 5. 8S ribosomal DNA typing in ocular infections. J Clin Microbiol. 2001;39(8): 2873-9.
15. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A3. Wayne: Clinical and Laboratory Standards Institute; 2008.
16. Aller AI, Martin-Mazuelos E, Lozano F, Gomez-Mateos J, Steele-Moore L, Holloway WJ, et al. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother. 2000;44(6): 1544-8.
17. Souza LKH, Fernandes OFL, Kobayashi CCBA, Passos XS, Costa CR, Lemos JA, et al. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil. Rev Inst Med Trop São Paulo. 2005;47(5): 253-6.
18. Lozano-Chiu M, Paetznick VL, Ghannoum MA, Rex JH. Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies. J Clin Microbiol. 1998;36(10): 2817-22.
19. Centers for Disease Control and Prevention. Epi Info™ versão 3. 5. 1. A Word processing, database and statistics program for public health. Atlanta: CDC; 2008. http://wwwn. cdc. gov/epiinfo/. Accessed 23 July 2012.
20. Ayres M, Ayres Jr. M, Ayres DL, Santos AAS. BioEstat® versão 5. 3: aplicações estatísticas nas áreas das ciências biomédicas. Belém: ONG Mamirauá; 2007.
21. Del Poeta M, Chaturvedi V. Cryptococcus and cryptococcosis in the twenty-first century. Mycopathologia. 2012; doi: 10. 1007/s11046-012-9544-9.
22. Monteiro DU, Brum TF, Noal CB, Righi RA, Santos ER, Oliveira LTO, et al. Prevalência de Candida e Cryptococcus em hemoculturas oriundas de pacientes do Hospital Universitário de Santa Maria, RS (HUSM) no ano de 2006. Saúde (Santa Maria). 2011;37(2): 81-8.
23. Rozenbaum R, Gonçalves AJR. Clinical epidemiological study of 171 cases of cryptococcosis. Clin Infect Dis. 1994;18(3): 369-80.
24. Lindenberg ASC, Chang MR, Paniago AMM, Lazéra MS, Moncada PMF, Bonfim GF, et al. Clinical and epidemiological features of 123 cases of cryptococcosis in Mato Grosso do Sul, Brazil. Rev Inst Med Trop São Paulo. 2008;50(2): 75-8.
25. Freire AKL, Bentes AS, Sampaio IL, Matsuura ABJ, Ogusku MM, Salem JI, et al. Molecular characterisation of the causative agents of Cryptococcosis in patients of a tertiary healthcare facility in the state of Amazonas-Brazil. Mycoses. 2012; doi: 10. 1111/j. 1439-0507. 2012. 02173. x.
26. Santos WRA, Meyer W, Wanke B, Costa SPSE, Trilles L, Nascimento JLM, et al. Primary endemicCryptococcosis gattii by molecular type VGII in the state of Pará, Brazil. Mem Inst Oswaldo Cruz. 2008;103(8): 813-8.
27. Corrêa MPSC, Oliveira EC, Duarte RRBS, Pardal PPO, Oliveira FM, Severo LC. Cryptococcosis in children in the state of Pará, Brazil. Rev Soc Bras Med Trop. 1999;32(5): 505-8.
28. Darzé C, Lucena R, Gomes I, Melo A. Clinical and laboratory characteristics of 104 cryptococcus meningoencephalitis cases. Rev Soc Bras Med Trop. 2000;33(1): 21-6.
29. Mora DJ, Colombo ERC, Ferreira-Paim K, Andrade-Silva LE, Nascentes GAN, Silva-Vergara ML. Clinical, epidemiological and outcome features of patients with cryptococcosis in Uberaba, Minas Gerais, Brazil. Mycopathologia. 2012; doi: 10. 1007/s11046-011-9504-9.
30. Yuchong C, Fubin C, Jianghan C, Fenglian W, Nan X, Minghui Y, et al. Cryptococcosis in China (1985-2010): review of cases from Chinese database. Mycopathologia. 2012; doi: 10. 1007/s11046-011-9471-1.
31. Favalessa OC, Ribeiro LC, Tadano T, Fontes CJF, Dias FB, Coelho BPA, et al. First description of phenotypic profile and in vitro drug susceptibility of Cryptococcus spp. yeast isolated from HIV-positive and HIV-negative patients in State of Mato Grosso. Rev Soc Bras Med Trop. 2009;42(6): 661-5.
32. Mondon P, Petter R, Amalfitano G, Luzzati R, Concia E, Polacheck I, et al. Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans. Antimicrob Agents Chemother. 1999;43(8): 1856-61.
33. Silva PR, Rabelo RAS, Terra APS, Teixeira DNS. Susceptibility to antifungal agents among Cryptococcus neoformans varieties isolated from patients at a university hospital. Rev Soc Bras Med Trop. 2008;41(2): 158-62.